Brazil's obesity rise fuels GLP‑1 drug scrutiny and reshapes food‑service consumer habits

A panel at the "Jornada de vida" event highlighted obesity as a chronic, multifactorial disease and emphasized that even modest weight loss (2.5‑5% of body weight) can improve glycemic control. Endocrinologists and a content creator stressed the importance of sustainable methods and warned against the "yo‑yo" effect.

The Brazilian health regulator ANVISA clarified the classification of GLP‑1 weight‑loss medications, distinguishing authorized products from falsified, experimental, and irregularly imported ones to help patients avoid unsafe drugs.

The ABF Rio conference in Barra da Tijuca examined how GLP‑1 users are altering eating habits outside the home. According to GALUNION data, 91% of Brazilian users report seeking smaller portions, higher protein and fiber foods, and fewer fried items, prompting restaurants to consider flexible menus, portion redesign, and functional beverages.

Health data show obesity prevalence in Brazil has risen 118% among adults between 2006 and 2024, with 68% of adults overweight and 31% obese, contributing to over 60,000 premature deaths in 2021. Physicians note patients are now better informed about drugs such as semaglutide and tirzepatide, but stress that medication must be combined with comprehensive clinical evaluation and lifestyle changes.